Clinical case of mitotically active uterine leiomyoma

One of the rare variants of uterine smooth muscle tumors is mitotically active leiomyoma, histological characteristics of which are defined by a high number of mitoses in the absence of necrosis and cellular atypia. Despite the presence of mitotic activity, this tumor process is benign. Mitotically active leiomyoma of the uterus is usually diagnosed in patients in the perimenopausal period and its size typically does not exceed 10 cm. This article presents a rare clinical case of a giant-sized mitotically active leiomyoma of the uterus in a woman of reproductive age. Attention is drawn to the challenges in clinical diagnosis and the difficulties in differentiation from malignant neoplasms. The primary treatment method for mitotically active leiomyoma of the uterus is surgical (myomectomy or hysterectomy as indicated). According to several publications, no recurrence of this pathology was observed during patient follow-up after surgical treatment ranging from 6 months to 15 years. Considering the clinical and macroscopic similarity of mitotically active leiomyoma with leiomyosarcoma, careful histological verification of the diagnosis is necessary to determine the correct management strategy.

1. Giuliani E., As-Sanie S., Marsh E.E. Epidemiology and management of uterine fi broids. Int. J. Gynaecol. Obstet. 2020;149(1):3–9. DOI: 10.1002/ijgo.13102

2. Stewart E.A., Laughlin-Tommaso S.K., Catherino W.H., Lalitkumar S., Gupta D., Vollenhoven B. Uterine fi broids. Nat. Rev. Dis. Primers. 2016;2:16043. DOI: 10.1038/nrdp.2016.43

3. Stewart E.A., Cookson C.L., Gandolfo R.A., Schulze-Rath R. Epidemiology of uterine fi broids: a systematic review. BJOG. 2017;124(10):1501–1512. DOI: 10.1111/1471-0528.14640

4. Pavone D., Clemenza S., Sorbi F., Fambrini M., Petraglia F. Epidemiology and Risk Factors of Uterine Fibroids. Best Pract. Res. Clin. Obstet. Gynaecol. 2018;46:3–11. DOI: 10.1016/j.bpobgyn.2017.09.004

5. Salehi A.M., Jenabi E., Farashi S., Aghababaei S., Salimi Z. Risk factors related to uterine leiomyoma: An umbrella review. J. Gynecol. Obstet. Hum. Reprod. 2023;52(1):102517. DOI: 10.1016/j.jogoh.2022.102517

6. Tak Y.J., Lee S.Y., Park S.K. et al. Association between uterine leiomyoma and metabolic syndrome in parous premenopausal women: a case-control study. Med. Baltim. 2016;95(46):e5325.

7. Zepiridis L.I., Grimbizis G.F., Tarlatzis B.C. Infertility and uterine fi broids. Best Pract. Res. Clin. Obstet. Gynaecol. 2016:34:66–73. DOI: 10.1016/j.bpobgyn.2015.12.001

8. Pérez-López F.R., Ornat L., Ceausu I., et al. EMAS position statement: management of uterine fi broids. Maturitas. 2014;79(1):106–116. DOI: 10.1016/j.maturitas

9. De La Cruz M.S., Buchanan E.M. Uterine fi broids: diagnosis and treatment. Am Fam Physician. 2017;95(2):100–107.

10. Donnez J., Dolmans M.-M. Uterine fi broid management: from the present to the future. Hum. Reprod. Update. 2016;22(6):665–686. DOI: 10.1093/humupd/dmw023

11. Ichigo S., Takagi H., Matsunami K., Suzuki N., Imai A. Benefi cial eff ects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist. Arch. Gynecol. Obstet. 2011;284(3):667–70. DOI: 10.1007/s00404-010-1732-6

12. Mas A., Tarazona M., Carrasco J.D., Estaca G., Cristóbal I., Monleón J. Updated approaches for management of uterine fi broids. Int. J. Womens Health. 2017:9:607–617. DOI: 10.2147/IJWH. S138982

13. Quinn S.D., Vedelago J., Gedroyc W., Regan L. Safety and fi veyear re-intervention following magnetic resonance-guided focused ultrasound (MRgFUS) for uterine fi broids. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014.182:247–251. DOI: 10.1016/j.ejogrb.2014.09.039

14. El Hilali F., Aalalou H., Lemine M.M., et al. Mitotically active leiomyomas of the uterus: about two cases. International Journal of Advanced Research. 2021;9(1):143–146. DOI:10.21474/IJAR01/12287

15. Prayson R.A., Hart W.R. Mitotically active leiomyomas of the uterus. Am. J. Clin. Pathol. 1992;97(1):14–20. DOI: 10.1093/ajcp/97.1.14

16. Perrone T., Dehner L.P. Prognostically favorable “mitotically active” smooth-muscle tumors of the uterus. A clinicopathologic study of ten cases. Am. J. Surg. Pathol. 1988;12(1):1–8. DOI: 10.1097/00000478-198801000-00001

17. Hendrickson M.R. et al. Mesenchymal Tumors and Related Lesions In: World Health Organisation Classifi cation of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. 2003.

18. Devereaux K.A., Schoolmeester J.K. Smooth Muscle Tumors of the Female Genital Tract. Surg. Pathol. Clin. 2019;12(2):397–455. DOI: 10.1016/j.path.2019.02.004

19. Bell S.W., Kempson R.L., Hendrickson M.R. Problematic uterine smooth muscle neoplasms. A Clinicopathologic study of 213 cases. Am. J. Surg. Pathol. 1994;18(6):535–558.

20. Dgani R., Piura B., Ben-Baruch G. et al. Clinical-pathological study of uterine leiomyomas with high mitotic activity. Acta Obstet. Gynecol. Scand. 1998;77(1):74–77. DOI: 10.1034/j.1600-0412.1998.770116.x